设计和优化具有有前途的抗癌活性的螺旋 - 伊萨 - 提阿佐利丁混合物
Dmytro Khylyuk1, Serhii Holota2,3, Natalia Finiuk4
1Chair and Department of Organic Chemistry, Medical University of Lublin, ul. Chodźki 4a, 20-093 Lublin, Poland.
Pharmaceuticals (Basel, Switzerland)
|October 29, 2025
概括
通过抑制MDM2-p53相互作用,新型的螺旋-伊萨-提阿索利丁混合体显示出强大的抗癌活性. 化合物18表现出高选择性和有利的类似药物的特性,为癌症治疗提供了一个有希望的新策略.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 分子药理学分子药理学
背景情况:
- 癌症仍然是一个重大的全球健康挑战,目前治疗方法的局限性.
- 向MDM2-p53相互作用是由于瘤中途径失调的关键抗癌策略.
- 螺旋-伊萨-提亚索利丁衍生物显示出潜力,但需要优化功效和选择性.
研究的目的:
- 设计,合成和评估新型的螺旋-伊萨-提阿索利丁混合体.
- 增强对癌细胞的细胞毒性,同时减少对正常细胞的毒性.
- 研究这些杂交物作为向MDM2-p53通路的抗癌剂的潜力.
主要方法:
- 对MDM2进行分子对接,用于衍生设计和优化.
- 在体外细胞毒性评估使用MTT测定各种癌症和正常细胞系.
- 分子动力学模拟用于结合稳定性评估和in silico ADMET属性预测.
主要成果:
- 几种衍生品显示微分子细胞毒性.
- 化合物18表现出强大和选择性的抗癌活性 (癌细胞中的IC50 6.67-8.37μM,HaCaT细胞中的≥100μM).
- 化合物18显示出强大的MDM2结合亲和力,稳定的相互作用,良好的口服生物可用性,并符合Lipinski的五项规则.
结论:
- 新型的螺旋-伊萨-提阿索利丁杂交物,特别是18化合物,具有强大和选择性的抗癌特性.
- 化合物18显示出有利的药理动力学和毒性概况,表明其治疗潜力.
- 这些发现支持开发螺旋-伊萨- thiazolidinone 衍生物作为向抗癌剂.
![Solid-phase Synthesis of [4.4] Spirocyclic Oximes](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58508.jpg&w=3840&q=50)
相关概念视频
01:28Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
01:27Combined Effects of Drugs: Synergism
6.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.7K